Conferences
IBCN 2024: AI in Bladder Cancer: The Good, the Bad, and the Ugly
September 21, 2024
IBCN 2024: AI-Enabled Bladder Cancer Grading: Externally Validating Quantitative Nuclear Features and Demonstrating Their Potential to Better Predict Time to Recurrence
September 20, 2024
IBCN 2024: Circulating Immune-Modulators of Response to Neoadjuvant Nivolumab + Nab-Paclitaxel in Muscle Invasive Bladder Cancer: Biomarker Analyses from Nure-COMBO Trial
September 20, 2024
IBCN 2024: Investigating BCG Induced B Cell Responses in Patients with Non-Muscle Invasive Bladder Cancer
September 20, 2024
IBCN 2024: Correlation of ctDNA Dynamics with Clinical Response in MIBC Patients Undergoing Trimodality Therapy
September 20, 2024
IBCN 2024: Keynote Lecture: Inferring Tumor Evolution from Single-Cell Data
September 20, 2024
IBCN 2024: Elucidating the Response Rates to Additional BCG: Implications for Clinical Trial Design
September 20, 2024
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
September 17, 2024
ESMO 2024: Controversies in Testis Cancer: Escalation or De-escalation?
September 17, 2024
ESMO 2024: Invited Discussant: JCOG1019, TOMBOLA, and SunRISe-4
September 17, 2024